Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients

Digestive Diseases and Sciences

Volumn 57, Issue 9, 2012, Pages 2394-2401

  Wroblova, Katerina ^a   Kolorz, Michal ^a   Batovsky, Marian ^b   Zboril, Vladimir ^c   Suchankova, Jana ^a   Bartos, Milan ^a   Ulicny, Boris ^d   Pav, Igor ^b   Bartosova, Ladislava ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d YBUX Ltd   (Czech Republic)

Author keywords

Azathioprine; Inflammatory bowel disease; Inosine triphosphate diphosphatase; Pharmacogenomics; Thiopurine S methyltransferase; Xanthine dehydrogenase

Indexed keywords

AZATHIOPRINE; HYDROLASE; INOSINE TRIPHOSPHATE DIPHOSPHATASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE;

ALLELE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; DNA POLYMORPHISM; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; ENTERITIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; PANCREATITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AZATHIOPRINE; GASTROINTESTINAL DISEASES; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOPENIA; METHYLTRANSFERASES; PANCREATITIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 84866431701     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2163-y     Document Type: Article

References (47)

1. Stocco G, Cheok MH, Crews KR, Dervieux T, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;2:164-172.
2. Al Hadithy AFY, de Boer NKH, Derijks LJJ, Escher JC, Mulder CJJ, Brouwers JRBJ. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005;4:282-297. (Pubitemid 41070528)
3. Patel AA, Swerlick RA, Mccall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;3:369-389. (Pubitemid 44189574)
4. Roberts-Thomson C, Butler WJ. Azathioprine, 6-mercaptopurine and thiopurine S-methyltransferase. J Gastroenterol Hepatol. 2005;6:955. (Pubitemid 40897185)
5. Ansari A, Hassan C, Duley J, Marinaki A, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;10:1743-1750.
6. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 2005;7:826-833. (Pubitemid 40975585)
7. Connell WR, Kamm MA, Ritchie JK, Lennardjones JE. Bone-marrow toxicity caused by azathioprine in inflammatory bowel-disease27 years of experience. Gut. 1993;8:1081-1085. (Pubitemid 23245359)
8. Marinaki AM, Ansari A, Duley JA, Arenas M, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;3:181-187. (Pubitemid 38373112)
9. Yates CR, Krynetski EY, Loennechen T, Fessing MY, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;8:608-614. (Pubitemid 27172187)
10. Kolorz M, Bartosova L, Hosek J, Dvorackova D, et al. Importance of thiopurine S-Methyltransferase gene polymorphisms for prediction of azathioprine toxicity. Neuroendocrinol Lett. 2009;30:137-142.
11. Zelinkova Z, Derijks LJJ, Stokkers PCF, Vogels EWM, et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;1:44-49. (Pubitemid 43129523)
12. Colombel JF, Ferrari N, Debuysere H, Marteau P, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;6:1025-1030. (Pubitemid 30346978)
13. Evans WE, Hon YY, Bomgaars L, Coutre S, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;8:2293-2301. (Pubitemid 32366982)
14. Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol. 2009;5:533-540.
15. Dubinsky MC, Lamothe S, Yang HY, Targan SR, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;4:705-713. (Pubitemid 30171620)
16. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C > A and g.IVS2 + 21A > C sequence variants contribute to missplicing of the ITPA gene. Biochimica et Biophysica Acta Mol Basis Dis. 2007;1:96-102. (Pubitemid 44960729)
17. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics. 2007;9:1221-1228. (Pubitemid 47578231)
18. Heller T, Oellerich M, Armstrong VW, Von Ahsen N. Rapid detection of ITPA 94C > A and IVS2 + 21A > C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A > C polymorphism on splicing efficiency. Clin Chem. 2004;11:2182-2184. (Pubitemid 39425868)
19. Derijks LJJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des. 2010;2:145-154.
20. Parks DA, Granger DN. Xanthine-oxidasebiochemistry, distribution and physiology. Acta Physiol Scand. 1986;548:87-99.
21. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine-oxidasenature and extent of individual variation. Clin Pharmacol Ther. 1991;6:663-672.
22. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine-oxidase, and Cyp1A2 activities. Clin Pharmacol Ther. 1992;6:643-658. (Pubitemid 23001871)
23. Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol. 2004;3:454-463. (Pubitemid 38230847)
24. Kudo M, Moteki T, Sasaki T, Konno Y, et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics. 2008;3:243-251. (Pubitemid 351323239)
25. Maeda T, Sumi S, Ueta A, Ohkubo Y, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab. 2005;4:271-279. (Pubitemid 41074110)
26. Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24). Pharmacogenet Genomics. 2008;10:887-893.
27. de la Moureyre CSV, Debuysere H, Mastain B, Vinner E, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol. 1998;4:879-887. (Pubitemid 28482633)
28. Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol. 2004;2:89-96. (Pubitemid 38626437)
29. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ther. 2001;2:183-188. (Pubitemid 32777771)
30. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem. 2004;41:294-302. (Pubitemid 38954878)
31. Regueiro M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol. 2002;3:240-244. (Pubitemid 34913091)
32. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008;6:654-660.
33. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut. 2003;1:140-142. (Pubitemid 36020781)
34. Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009;4:375-384.
35. http://www.ncbi.nlm.nih.gov/projects/SNP/snp-ref.cgi?rs=4407290, Accessed July 7, 2011.
36. van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EES, Kuipers EJ, van der Woude CJ. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut. 2005;11:1664. (Pubitemid 41531793)
37. Sumi S, Marinaki AM, Arenas M, Fairbanks L, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;4-5:360-367. (Pubitemid 36075062)
38. Herting G, Barber K, Zappala MR, Cunningham RP, Burgis NE. Quantitative in vitro and in vivo characterization of the human P32T mutant ITPase. Biochim Biophys Acta. 2010;2:269-274.
39. Marsh S, King CR, Ahluwalia R, Mcleod HL. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet. 2004;10:579-581. (Pubitemid 39506541)
40. Cao HN, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;11:620-622. (Pubitemid 36083264)
41. Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;4:517-528.
42. Shipkova M, Lorenz K, Oellerich M, Wieland E, Von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem. 2006;2:240-247. (Pubitemid 43185485)
43. Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut. 2005;4:565.
44. Zabala-Fernández W, Barreiro-de Acosta M, Echarri A, Carpio D, et al. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. J Gastrointes Liver Dis. 2011;20:247-253.
45. Cuffari C, Dassopoulos T, Turnbaugh L, Thompson R, Bayless TM. Thiopurine methyltransferase (TPMT) activity influences clinical response to maintenance azathioprine therapy in patients with IBD. Gastroenterology. 2002;4:A221.
46. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;10:2239-2247.
47. Priest VL, Begg EJ, Gardiner SJ, Frampton CMA, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006;8:767-781. (Pubitemid 44232105)